Extended Data Figure 8: Progression-free Survival in Glioblastoma as a Function of PD-1 inhibitor-Induced BCR Diversity.

Left: Progression-free survival in glioblastoma patients who underwent resection then started on adjuvant PD1 inhibitor. Tumor collection on which BCR clonotype analysis was performed was prior to PD1 exposure (Cloughesy et al. 2019). P values reported for log rank test.

Right: Progression-free survival in glioblastoma patients exposed to neoadjuvant PD1 inhibitor followed by surgical resection.